What are Lawrence Jasinski’s direct LMAT share holdings after these transactions?

After the May 7, 2026 transactions, he directly holds 4,714 LeMaitre Vascular common shares. This post-transaction total appears in the row reporting the 3,943-share open-market sale and reflects his remaining direct equity stake following the exercise-and-sell activity.

What stock option positions related to LMAT did the director exercise in this filing?

He exercised three stock option grants, each labeled "Stock Option (Right to Buy)." These covered 865 shares at a $101.12 exercise price, 924 shares at $54.65, and 1,069 shares at $47.19, converting derivative awards into LeMaitre Vascular common stock.

LeMaitre Vascular (LMAT) director exercises options, then sells 3,943 shares

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

LeMaitre Vascular director Lawrence J. Jasinski reported an exercise-and-sell transaction in company stock. On May 7, 2026, he sold 3,943 shares of common stock in an open-market sale at $110.00 per share, leaving him with 4,714 directly held shares afterward.

On the same date, he exercised stock options to acquire a total of 2,858 common shares at exercise prices of $101.12, $54.65, and $47.19 per share. Related option entries show remaining option positions in multiple grants following these exercises. Overall, the filing reflects a combination of option exercises and a net sale of shares.

Insider Trade Summary

Net Seller: 3,943 shares ($433,730)

Net Sell 7 txns

Insider Jasinski Lawrence J

Role null

Sold 3,943 shs ($434K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	1,069	$0.00	--
Exercise	Stock Option (Right to Buy)	924	$0.00	--
Exercise	Stock Option (Right to Buy)	865	$0.00	--
Exercise	Common Stock	1,069	$47.19	$50K
Exercise	Common Stock	924	$54.65	$50K
Exercise	Common Stock	865	$101.12	$87K
Sale	Common Stock	3,943	$110.00	$434K

Holdings After Transaction: Stock Option (Right to Buy) — 2,140 shares (Direct, null); Common Stock — 6,868 shares (Direct, null)

Footnotes (1)

Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II. This option is fully vested and exercisable. This option is exercisable and vests over a three-year period at a rate of 33.3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years.

Key Figures

Open-market sale: 3,943 shares at $110.00/share Shares after sale: 4,714 shares Options exercised (total shares): 2,858 shares +4 more

7 metrics

Open-market sale 3,943 shares at $110.00/share Common Stock sale on May 7, 2026

Shares after sale 4,714 shares Direct common stock holdings following sale

Options exercised (total shares) 2,858 shares Common shares acquired via option exercise on May 7, 2026

Option exercise price $101.12/share 865-share stock option grant converted to common stock

Option exercise price $54.65/share 924-share stock option grant converted to common stock

Option exercise price $47.19/share 1,069-share stock option grant converted to common stock

Net buy/sell shares -3,943 shares Transaction summary netBuySellShares

Key Terms

open-market sale, Stock Option (Right to Buy), Exercise or conversion of derivative security, fully vested and exercisable, +1 more

5 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

fully vested and exercisable financial

"footnote: "This option is fully vested and exercisable.""

vests over a three-year period financial

"footnote: "This option is exercisable and vests over a three-year period...""

Form 4 Insider Transactions: What Each Field Means →

05/11/2026 - 05:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jasinski Lawrence J

(Last)

(First)

(Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/07/2026		M		1,069⁽¹⁾	A	$47.19	6,868	D
Common Stock	05/07/2026		M		924⁽¹⁾	A	$54.65	7,792	D
Common Stock	05/07/2026		M		865⁽¹⁾	A	$101.12	8,657	D
Common Stock	05/07/2026		S		3,943	D	$110	4,714	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$47.19	05/07/2026		M			1,069	12/12/2022⁽²⁾	12/12/2027	Common Stock	1,069	$0	2,140	D
Stock Option (Right to Buy)	$54.65	05/07/2026		M			924	12/08/2023⁽³⁾	12/08/2028	Common Stock	924	$0	1,848	D
Stock Option (Right to Buy)	$101.12	05/07/2026		M			865	12/06/2024⁽³⁾	12/06/2029	Common Stock	865	$0	1,729	D

Explanation of Responses:

1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.

2. This option is fully vested and exercisable.

3. This option is exercisable and vests over a three-year period at a rate of 33.3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years.

	/s/ Laurie A. Churchill, Attorney-in-fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did LMAT director Lawrence Jasinski report on May 7, 2026?

Director Lawrence Jasinski reported an exercise-and-sell sequence on May 7, 2026. He exercised stock options for 2,858 LeMaitre Vascular common shares, then sold 3,943 shares in an open-market sale, combining derivative exercises with a net reduction in directly held stock.

How many LeMaitre Vascular (LMAT) shares did the director sell and at what price?

He sold 3,943 LeMaitre Vascular common shares in an open-market sale at a price of $110.00 per share. This sale reduced his directly held position and is the only transaction in the filing coded as an open-market sale.

How many LMAT shares did the director acquire through option exercises in this Form 4?

He acquired 2,858 LeMaitre Vascular common shares by exercising stock options. The exercised tranches were 865 shares at $101.12, 924 shares at $54.65, and 1,069 shares at $47.19, all reported as derivative exercises converting options into common stock.

Does the LMAT Form 4 indicate any gifts or tax-withholding transactions?

The Form 4 transaction summary shows no gifts or tax-withholding entries. GiftCount and taxWithholdingCount are both zero, and there are no transactions coded as G or F, indicating the filing only includes option exercises and an open-market sale.